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Abstract: Background: Numerous driver mutations have been identified in colorectal cancer (CRC),
but their relevance to the development of targeted therapies remains elusive. The secondary effects of
pathogenic driver mutations on downstream signaling pathways offer a potential approach for the
identification of therapeutic targets. We aimed to identify differentially expressed genes as potential
drug targets linked to driver mutations. Methods: Somatic mutations and the gene expression data of
582 CRC patients were utilized, incorporating the mutational status of 39,916 and the expression levels
of 20,500 genes. To uncover candidate targets, the expression levels of various genes in wild-type
and mutant cases for the most frequent disruptive mutations were compared with a Mann–Whitney
test. A survival analysis was performed in 2100 patients with transcriptomic gene expression
data. Up-regulated genes associated with worse survival were filtered for potentially actionable
targets. The most significant hits were validated in an independent set of 171 CRC patients. Results:
Altogether, 426 disruptive mutation-associated upregulated genes were identified. Among these, 95
were linked to worse recurrence-free survival (RFS). Based on the druggability filter, 37 potentially
actionable targets were revealed. We selected seven genes and validated their expression in 171
patient specimens. The best independently validated combinations were DUSP4 (p = 2.6 × 10−12) in
ACVR2A mutated (7.7%) patients; BMP4 (p = 1.6 × 10−04) in SOX9 mutated (8.1%) patients; TRIB2
(p = 1.35 × 10−14) in ACVR2A mutated patients; VSIG4 (p = 2.6 × 10−05) in ANK3 mutated (7.6%)
patients, and DUSP4 (p = 7.1 × 10−04) in AMER1 mutated (8.2%) patients. Conclusions: The results
uncovered potentially druggable genes in colorectal cancer. The identified mutations could enable
future patient stratification for targeted therapy.
Keywords: colon cancer; disruptive mutations; oncogenes; molecular targeted therapy; survival
1. Introduction
Colorectal cancer (CRC) is a major cause of cancer-related deaths worldwide [1], with steeply
increasing rates in some developed countries [2], especially among adults aged <50 years [3]. About
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25% of patients are diagnosed with a metastatic disease and another 25% eventually develop metastases.
CRC is molecularly heterogeneous, with significantly varying response to therapeutic intervention
leading to poor prognosis among the majority of patients. In the early 2000s, treatment options, such
as traditional chemotherapy (primarily based on oxaliplatin, fluoropyrimidine, and irinotecan) were
complemented with more targeted approaches, such as the VEGF-inhibitor bevacizumab [4] and
the EGFR-targeting monoclonal antibodies, cetuximab and panitumumab [5,6]. These therapeutic
options resulted in an increased median survival of up to 30 months in the metastatic setting. Newer
therapies for metastatic CRC focus mainly on angiogenesis inhibition: ziv-aflibercept as a second line
treatment combined with FOLFIRI targets VEGF-A, VEGF-B, and PlGF [7], and the oral multi-kinase
inhibitor regorafenib, which obstructs multiple tumor pathways and targets VEGFR1-3, TIE2, PDGFR,
FGFR1, FGFR2, KIT and RET [8]. The recombinant fusion protein ramucirumab was approved in
2015 in combination with FOLFIRI, and inhibits ligand-stimulated activation of VEGFR2 receptors [9].
While many newer and developmental drugs such as these have multiple targets, the downstream
signaling pathways are not yet well characterized, hindering effective biomarker development for
patient stratification.
Recent efforts delivered CRC classifications using different molecular markers for patient
stratification [10]. Advances in molecular technology are helping to identify critical driver genomic
events associated with therapeutic response [11]. About 15% of tumors harbor microsatellite instability
(MSI) as a consequence of defective DNA Mismatch Repair (MMR) genes, and these tumors are highly
immunogenic. Cells with MMR defects are mutation-prone, particularly at microsatellite sequences,
with 10-times more somatic mutations compared to non-MMR deficient tumors [12]. For metastatic
dMMR/MSI-high disease, various immunotherapies (nivolumab, pembrolizumab and a combination of
ipilimumab and nivolumab [13]) have been available since 2017. Nevertheless, the majority of CRCs are
poorly immunogenic [14], and the evolution of targeted agents in CRC remains slow, mainly focusing on
a selection of patients for anti-EGFR therapy [11]. Numerous biomarkers that confer innate resistance
toward such agents have been described (e.g., mutations of KRAS and NRAS). Anti-EGFR therapy is
more likely to be effective in KRAS wild-type patients who also harbor wild types NRAS, BRAF and
PIK3CA, but this constellation appears only in up to 30% of the CRC patient population [15]. Overall,
the low prevalence of some molecular events limits their applicability as disease biomarkers [11].
The emergence of positive predictive biomarkers for alternative treatment selection (e.g., BRAFV600E
and RNF43 mutations, ALK and NTRK1 fusions) is also slow, mostly with limited response rates [11];
therefore the identification of actionable genetic targets is highly sought after.
CRC arises through a multi-step process of sequential accumulation of molecular alterations.
About five to seven oncogenic mutations are required for a malignant transformation [16], though
according to some studies, three driver events are sufficient for tumorigenesis [12]. There has been a
significant progress in identifying recurrent mutations over the past decades, and numerous oncogenes
and tumor suppressors (e.g., EGFR, APC, TP53, PTEN, SMAD4, FBXW7, SOX9, and ACVR2) have been
described [17]; however, to better understand the clinical significance and the underlying molecular
mechanisms of action, further research is required. Since mutations have mainly been investigated in
the context of the efficacy of anti-EGFR-therapy [11] and for most of them, targeted agents do not exist,
it is particularly important to investigate the downstream effects of driver events as potential drug
targets or markers of therapeutic outcome.
Driver mutations not only influence the gene itself and the corresponding protein production, but
also impact downstream signaling pathways. In fact, the secondary effects of mutations may have
stronger prognostic relevance than the primary genetic alterations [18], thus they might provide a
viable pipeline to select targets for clinical intervention. The primary aim of our study was to identify
differentially express genes as potential druggable targets linked to driver mutations. We focused on
the 10 most frequent disruptive mutations, identified significantly upregulated genes associated with
poor survival outcome and filtered out actionable genes to provide clinically relevant targets for drug
development. The expression of the top genes was validated in an independent clinical cohort.
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2. Methods
2.1. Sequencing and Expression Database
Expression and mutation data were retrieved from the TCGA repository (https://portal.gdc.
cancer.gov/). Mutations identified with the mutect2 algorithm were downloaded in VCF format. The
variations were chosen depending on their mutect2 ‘PASS’ status—mutations with 40x the overall
coverage and a minimum of 5 reads were selected. The remaining mutations were annotated using the
snpEff [19] program based on the GRCh38 human genome version. In the database construction, only
the canonical isoforms were selected. The mutations were categorized as any, coding, non-coding and
disruptive mutations, based on the impact on the protein sequence.
The disruptive mutations included those affecting the START or STOP codon, producing an early
stop codon, affecting the splice-site (but not the splice region), or creating frame shifts (insertions
and deletions affecting less than 3 nucleotides or exceeding the multiples of 3), as illustrated in
Figure 1A [20].
Cancers 2019, 11, x 3 of 14 
poor survival outcome and filtered out actionable genes to provide clinically relevant targets for drug 
development. The expression of the top genes was validated in an independent clinical cohort. 
2. Methods 
2.1. Sequencing and Expression Database 
Expression and mutation data were retrieved from the TCGA repository 
(https://portal.gdc.cancer.gov/). Mutations identified with the mutect2 algorithm were downloaded 
in VCF format. The variations were chosen depending on their mutect2 ‘PASS’ status—mutations 
with 40x the overall coverage and a minimum of 5 reads were selected. The remaining mutations 
were annotated using the snpEff [19] program based on the GRCh38 human genome version. In the 
database construction, only the canonical isoforms were selected. The mutations were categorized as 
any, coding, non-coding and disruptive mutations, based on the impact on the protein sequence. 
The disruptive mutations included those affecting the START or STOP codon, producing an 
early stop codon, affecting the splice-site (but not the splice region), or creating frame shifts 
(insertions and deletions affecting less than 3 nucleotides or exceeding the multiples of 3), as illustrated 
in Figure 1A [20]. 
 
 
 
Figure 1. Disruptive mutations are defined as mutations that result in a disrupted protein structure. 
(A) These include mutations affecting the START or STOP codons, producing an early stop codon, 
affecting the splice-site, or resulting in a frame shift. (B) The locations of the mutations within the 
ACVR2A, AMER1, SOX9, ANK3 and APC genes (larger circles represent recurrent mutations). Only 
mutations occurring in coding regions are included. 
A 
B 
Figure 1. Disruptive mutations are defined as mutations that result in a disrupted protein struct re. (A)
These include mutations affecting the START or STOP codons, producing an early stop codon, affecting
the splice-site, or resulting in a frame shift. (B) The locations of the mutations within the ACVR2A,
AME 1, SOX9, ANK3 and PC genes (larger circles represent recurrent mutations). Only mutations
occurring in coding regions are included.
The expression database was constructed from the raw HTseq-count read counts. The obtained
read counts were normalized using the DESeq2 [21] algorithm.
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2.2. Gene Selecting Algorithm
We split the specimens into two cohorts based on the mutation status. The normalized expression
of the wild-type and mutant specimens was compared by a Mann–Whitney test. Only disruptive
mutations were included, and we repeated the process for each selected gene. Statistical significance
was accepted in case of p < 0.01 and a fold change (FC) cutoff at 1.44. The Benjamini–Hochberg false
discovery rate was executed to safeguard against errors resulting from multiple hypothesis testing.
2.3. Survival Analysis
We searched PubMed Gene Expression Omnibus (GEO) data repository (https://www.ncbi.
nlm.nih.gov/geo/) to identify colorectal cancer datasets with published survival times, as described
previously [10]. The raw data were re-normalized, and the datasets were combined into a single
database. To select the most reliable probe set for each gene, we used JetSet, a tool measuring and
comparing different quality parameters for each probe set [22]. Survival analysis was performed for
the selected genes using Cox proportional hazards regression. The analysis was performed using the
auto-select best cutoff function, whereby all the possible cutoff values between the upper and lower
quartiles were computed and the best performing threshold was used as a cutoff. Kaplan–Meier plots
were drawn to visualize survival differences.
2.4. CRC Specimens for the Validation Cohort
For the clinical validation set up to identify top genes, we analyzed formalin-fixed
paraffin-embedded (FFPE) cancer tissues from 171 CRC patients who underwent surgery at the
Tokyo Medical and Dental University Hospital (TMDU), Tokyo, Japan from 2007 to 2011. All cases were
histologically confirmed as adenocarcinoma and were classified into tumor-node-metastasis (TNM)
stages after surgery according to the American Joint Committee on Cancer (AJCC), 7th edition. This
study was conducted in accordance with the Declaration of Helsinki. All the procedures associated
with this study were approved by the Institutional Review Boards of the Baylor Scott & White Research
Institute (approval number: 003-180), and all the patients provided written informed consent.
2.5. Nucleic Acid Isolation and Gene Expression Analysis
The total RNA was isolated from the FFPE tissues using an ALL Prep DNA/RNA FFPE kit (Qiagen,
Valencia, CA, USA). A synthesis of the complementary DNA (cDNA) was conducted with 500ng of the
total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City,
CA, USA). qRT-PCR was performed using the SensiFAST™ SYBR® Lo-ROX Kit (Bioline, London, UK)
on the Quantstudio 7 Real Time PCR System (Applied Biosystems). The relative expression levels of
the target genes were normalized against beta-actin using the 2−∆CT method. The PCR primers used in
the current study are shown in Table S1.
2.6. Availability of Data and Material
Expression and mutation data were retrieved from the TCGA repository (https://portal.gdc.cancer.
gov/).
3. Results
3.1. Database Setup
Data from 459 patients diagnosed with colon adenocarcinomas (COAD) and 170 patients with
rectal adenocarcinomas (READ) were available from the TCGA repository, including a small subset
of patients diagnosed with mucinous adenocarcinomas (COAD: 13.5%; READ: 7.6%). Most COAD
patients were diagnosed with a clinical stage II disease, while roughly an equal number of READ
patients were diagnosed with stage II and III disease. Altogether 55.4% of COAD patients were
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diagnosed in either stage I (16.6%) or stage II (38.8%), and about half (49.4%) of READ patients were
diagnosed in stage I/II (stage I: 19.4%; stage II: 30.0%) (Table S2). The balanced incorporation of tumors
with early and more advanced disease stages avoids selection bias for more aggressive tumors.
Venous invasion was present in about one fifth of all patients, and over one third of the patients
were diagnosed with lymph node involvement. Males were slightly overrepresented in both COAD
and READ. Over two third of patients were 60 years of age or older, with a median age of 68 years in
COAD, and 66 years in READ. Residual disease was absent after surgery in most patients (COAD:
72.1%; READ: 74.7%). During the median follow-up period (COAD: 22.3 months; READ: 20.58 months),
22.2% of COAD and 15.9% of READ patients died. Only a small proportion (2.4%) of COAD patients
and none of the READ patients were identified with MSI-high disease, although information about
MSI was lacking for most patients (for details see Table S2). We combined the COAD and READ
datasets when comparing mutation status and gene expression levels to increase the statistical power
of the analysis.
3.2. Frequently Mutated Genes
Altogether, 53,373 disruptive mutations were identified in the sample population affecting 14,021
out of 39,916 coding and non-coding genes, as annotated by snpEff (http://snpeff.sourceforge.net/index.
html) [19]. The mutations displayed a skewed distribution: most mutations appeared in very few cases
(1–2 specimens), while only 10 genes (excluding TTN) were mutated in more than 40 patients. The 40
most frequently mutated genes are listed in Table S3. We selected the top ten (excluding TTN) most
frequently mutated genes (APC, TP53, SYNE1, AMER1, SOX9, ACVR2A, ANK3, ARID1A, FBXW7,
MDN1) (Figure 2) for subsequent analysis.
Cancers 2019, 11, x 5 of 14 
3. Results 
3.1. Database Setup 
Data from 459 patients diagnosed with colon adenocarcinomas (COAD) and 170 patients with 
rectal adenocarcinomas (READ) were available from the TCGA repository, including a small subset 
of patients diagnosed with mucinous adenocarcinomas (COAD: 13.5%; READ: 7.6%). Most COAD 
patients were diagnosed with a clinical stage II disease, while roughly an equal number of READ 
patients were diagnosed with stage II and III disease. Altogether 55.4% of COAD patients were 
diagnosed in either stage I (16.6%) or stage II (38.8%), and about half (49.4%) of READ patients were 
diagnosed in stage I/II (stage I: 19.4%; stage II: 30.0%) (Table S2). The balanced incorporation of 
tumors with early and more advanced disease stages avoids selection bias for more aggressive 
tumors. 
Venous invasion was present in about one fifth of all patients, and over one third of the patients 
were diagnosed with lymph node involvement. Males were slightly overrepresented in both COAD 
and READ. Over two third of patients were 60 years of age or older, with a median age of 68 years in 
COAD, and 66 years in READ. Residual disease was absent after surgery in most patients (COAD: 
72.1%; READ: 74.7%). During the median follow-up period (COAD: 22.3 months; READ: 20.58 
months), 22.2% of COAD and 15.9% of READ patients died. Only a small proportion (2.4%) of COAD 
patients and none of the READ patients were identified with MSI-high disease, although information 
about MSI was lacking for most patients (for details see Table S2). We combined the COAD and 
READ datasets when comparing mutation status and gene expression levels to increase the statistical 
power of the analysis. 
3.2. Frequently Mutated Genes 
Altogether, 53,373 disruptive mutations were identified in the sample population affecting 
14,021 out of 39,916 coding and non-coding genes, as annotated by snpEff 
(http://snpeff.sourceforge.net/index.html) [19]. The mutations displayed a skewed distribution: most 
mutations appeared in very few cases (1–2 specimens), while only 10 genes (excluding TTN) were 
mutated in more than 40 patients. The 40 most frequently mutated genes are listed in Table S3. We 
selected the top ten (excluding TTN) most frequently mutated genes (APC, TP53, SYNE1, AMER1, 
SOX9, ACVR2A, ANK3, ARID1A, FBXW7, MDN1) (Figure 2) for subsequent analysis. 
 
Figure 2. Distribution of the 10 most frequent disruptive mutations in the training cohort. Each 
column corresponds to a single patient. In some cases, multiple genes were co-mutated within the 
Figure 2. Distribution of the 10 most frequ nt disruptive mutations n the training cohort. Each column
corresponds to a single p tie t. In some case , ultiple genes w re co-mutat d within the same tumor.
Mutations are grouped based on sex (female—red, male—gray) and stage (shades of blue).
The presence of selected disruptive mutations was not linked to patient sex in the entire dataset,
nor to tumor stage in READ, although in COAD, two mutations remained differently distributed across
tumor stages after multiple testing corrections: the ACVR2A mutations were linked to earlier tumor
stages (stages I/II, p = 0.007) while the APC mutations were associated with an advanced disease (stage
IV, p = 0.008). The locations of the disruptive mutations for the select genes are illustrated in Figure 1B.
The raw data of Figures 1B and 2 are presented in Tables S4 and S5. The expression levels of 20,500
genes were investigated in our patient population for correlation to each mutation.
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3.3. Survival Analysis
For each mutation, the top 50 upregulated genes were selected for subsequent survival analysis,
and all the genes were included when the number of upregulated genes was less than 50 (5 genes for
TP53 and 21 for AMER1). Out of the 426 upregulated genes, 95 were associated with worse outcome
(Table S6), while 177 overexpressed genes correlated with better relapse-free survival (p < 0.05). For
117 genes, the association between gene expression and clinical outcome was not significant, and 38
genes could not be identified in the transcriptomic dataset.
3.4. Selection of Potentially Actionable Genes
For potentially actionable genes, the Drug–Gene Interaction database DGIdb 3.0 [23] was analyzed.
The database aggregates druggable gene categories from multiple sources and predicts druggability by
various methods. Therefore, potentially actionable genes may or may not have existing drugs that
target them. Out of the 95 upregulated genes linked to worst survival, 37 were classified as theoretically
druggable (Table S6). We selected seven genes (TRIB2, TRIM7, DUSP4, PKM2, VSIG4, BMP4 and
IL1RN) based on MW p-values, expression differences, and effects on survival (Figures S1 and S2) for
subsequent clinical validation. Out of the gene list, two upregulated genes (TRIM7, DUSP4) were
linked to multiple mutations. The selection process of overexpressed genes linked to certain mutations
is illustrated in Figure 3 and the differential expression for the top genes is presented in Figure 4.Cancers 2019, 11, x 7 of 14 
 
Figure 3. Overview of the gene selection process in tumor specimens containing AMER1, SOX9, 
ACVR2A and ANK3 mutations. For each mutation, only the top 50 (or if less, all) upregulated genes 
were utilized in the subsequent survival analyses. The genes associated with worse survival were 
assessed for potential druggability, and the ultimately selected genes were validated in a clinical 
sample. 
 
Figure 4. Differential expression of genes in mutant and wild-type tumors. mRNA levels of TRIB2, 
DUSP4, VSIG4 and BMP4 are significantly higher in ACVR2A (TRIB2, DUSP4), ANK3 (VSIG4, 
Figure 3. Overview of the gene selection process in tu or speci ens containing A ER1, SOX9,
ACVR2A and ANK3 utations. For each utation, only the top 50 (or if less, all) upregulated genes
ere utilized in the subsequent survival analyses. The genes associated ith orse survival ere
assessed for potential druggability, and the ultimately selected genes were validated in a clinical sample.
Cancers 2019, 11, 983 7 of 14
Cancers 2019, 11, x 7 of 14 
 
Figure 3. Overview of the gene selection process in tumor specimens containing AMER1, SOX9, 
ACVR2A and ANK3 mutations. For each mutation, only the top 50 (or if less, all) upregulated genes 
were utilized in the subsequent survival analyses. The genes associated with worse survival were 
assessed for potential druggability, and the ultimately selected genes were validated in a clinical 
sample. 
 
Figure 4. Differential expression of genes in mutant and wild-type tumors. mRNA levels of TRIB2, 
DUSP4, VSIG4 and BMP4 are significantly higher in ACVR2A (TRIB2, DUSP4), ANK3 (VSIG4, 
Figure 4. Differential expression of genes in mutant and wild-type tumors. mRNA levels of TRIB2,
DUSP4, VSIG4 and BMP4 are significantly higher in ACVR2A (TRIB2, DUSP4), ANK3 (VSIG4, DUSP4),
SOX9 (BMP4) and AMER1 (DUSP4) mutant tumors compared to wild-type cases. The plots show
Q1/Q2/Q3 within min-max range.
3.5. Validation Sample Set
Altogether, 171 patient specimens were available for subsequent clinical validation of the selected
genes. The majority of the patients were diagnosed with stage II and III disease, with 45 mm median
tumor size. The median age at diagnosis was 67 years, although two third of the patient population
was at least 60 years old, with slight overrepresentation of males. The majority of patients were
diagnosed with the presence of venous invasion, and more than half with lymphatic invasion. The
median recurrence-free survival (RFS) was 50 months, and 26.9% of patients recurred during follow
up. The median overall survival (OS) was 60 months, and altogether, 19.9% of patients succumbed to
the disease. Only 6.3% of patients were identified with microsatellite instability (MSI)-high disease,
although information was unavailable for more than half of the patients. The characteristics of the
validation dataset are summarized in Table 1.
Table 1. Clinical characterization of the 171 CRC patients from the validation dataset.
Characteristic (%)
Sex
Male 55.6
Female 44.4
Age/Years
<60 24.6
≥60 75.4
Stage
I 9.9
II 41.5
III 41.5
IV 7.0
Venous Invasion
Present 86.0
Absent 13.5
N/A 0.6
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Table 1. Cont.
Characteristic (%)
Lymphatic Invasion
Present 57.9
Absent 41.5
N/A 0.6
Microsatellite Instability
Yes 6.4
No 42.7
N/A 50.9
Recurrence (Median Follow up 50 Months) 26.9
N/A—data unavailable.
3.6. Genes Associated with RFS in a Clinical Validation Set
The expression of the selected potentially actionable genes was validated with qPCR (Figure S3).
High expression of TRIB2 (p = 0.0003), VSIG4 (p = 0.0003), BMP4 (p = 0.023) and DUSP4 (p = 0.043)
was associated with worse RFS in the validation dataset (Figure 5), although the expression of TRIM7,
PKM2 and IL1RN was not significantly different between patients with or without disease recurrence
(p > 0.05). We used the median as a cutoff in the clinical validation cohort. We also analyzed RFS using
Youden Index as a cutoff value (please see Figure S4). The genes associated with survival disadvantage
were linked to mutations in ACVR2A (TRIB2, DUSP4), ANK3 (VSIG4, DUSP4), SOX9 (BMP4) and
AMER1 (DUSP4) (Figure 4).Cancers 2019, 11, x 9 of 14 
 
Figure 5. High expression of potentially actionable genes significantly associated with worse 
recurrence-free survival in the validation dataset. 
4. Discussion 
Despite the well-described driver genetic alterations in CRC, the availability of targeted 
therapies is limited, and the development of new personalized treatment methods has been rather 
slow. Mutations may impact downstream signaling pathways and alter the expression of potentially 
actionable genes. Evidence suggests that secondary genetic alterations may have a strong prognostic 
relevance [18], which provides an opportunity to utilize them in medical target selection. Following 
this approach, we identified four genes: TRIB2, VSIG4, BMP4, and DUSP4. These genes were 
overexpressed in CRC specimens with disruptive mutations, were linked to worse survival in 
multiple datasets and are deemed potentially actionable. The mutations affecting ACVR2A, ANK3, 
SOX9 and AMER1 may be utilized as biomarkers for patient stratification. 
TRIB2 (Tribbles Pseudokinase 2) belongs to the Tribbles family of proteins that are structurally 
similar to kinases but lack catalytic activity. Growing evidence suggests the role of TRIB2 as a pro-
oncogene with a regulatory function underlying drug resistance both in solid and hematological 
malignancies [24,25]. In concordance with our findings, elevated TRIB2 expression was linked to poor 
prognosis in CRC, with higher expression in patients with frequent disease recurrence [26]. 
Consistently, ectopic or intrinsic high expression of TRIB2 in CRC confers resistance to chemotherapy 
by activating AKT [27]. TRIB2 down-regulation inhibits proliferation, induces cell-cycle arrest and 
senescence in CRC cell lines [26]. TRIB2 is a potential novel therapeutic target both for acute myeloid 
leukemia (AML) and acute lymphoblastic leukemia (ALL) [28]. Recent drug repurposing approaches 
identified the small-molecule protein kinase inhibitors afatinib and neratinib as active substances in 
AML cell lines that rapidly degrade TRIB2, eliciting survival benefits [29]. Afatinib has already been 
investigated both as a monotherapy and in combination regimens in CRC patients, but with limited 
antitumor activity [30], although biomarker-driven patient recruitment may increase therapy 
effectiveness. In our dataset, elevated TRIB2 expression was specifically associated with the presence 
Figure 5. High expressi f te tiall actionable genes significantly associated with worse
recurrence-free survi al in the validation dat s t.
Cancers 2019, 11, 983 9 of 14
4. Discussion
Despite the well-described driver genetic alterations in CRC, the availability of targeted therapies is
limited, and the development of new personalized treatment methods has been rather slow. Mutations
may impact downstream signaling pathways and alter the expression of potentially actionable genes.
Evidence suggests that secondary genetic alterations may have a strong prognostic relevance [18],
which provides an opportunity to utilize them in medical target selection. Following this approach, we
identified four genes: TRIB2, VSIG4, BMP4, and DUSP4. These genes were overexpressed in CRC
specimens with disruptive mutations, were linked to worse survival in multiple datasets and are
deemed potentially actionable. The mutations affecting ACVR2A, ANK3, SOX9 and AMER1 may be
utilized as biomarkers for patient stratification.
TRIB2 (Tribbles Pseudokinase 2) belongs to the Tribbles family of proteins that are structurally
similar to kinases but lack catalytic activity. Growing evidence suggests the role of TRIB2 as a
pro-oncogene with a regulatory function underlying drug resistance both in solid and hematological
malignancies [24,25]. In concordance with our findings, elevated TRIB2 expression was linked to
poor prognosis in CRC, with higher expression in patients with frequent disease recurrence [26].
Consistently, ectopic or intrinsic high expression of TRIB2 in CRC confers resistance to chemotherapy
by activating AKT [27]. TRIB2 down-regulation inhibits proliferation, induces cell-cycle arrest and
senescence in CRC cell lines [26]. TRIB2 is a potential novel therapeutic target both for acute myeloid
leukemia (AML) and acute lymphoblastic leukemia (ALL) [28]. Recent drug repurposing approaches
identified the small-molecule protein kinase inhibitors afatinib and neratinib as active substances
in AML cell lines that rapidly degrade TRIB2, eliciting survival benefits [29]. Afatinib has already
been investigated both as a monotherapy and in combination regimens in CRC patients, but with
limited antitumor activity [30], although biomarker-driven patient recruitment may increase therapy
effectiveness. In our dataset, elevated TRIB2 expression was specifically associated with the presence
of ACVR2A mutations. ACVR2A (Activin A Receptor Type 2A) is one of the most frequently mutated
genes in hypermutated CRC [31]. ACVR2A encodes a transmembrane receptor, which is a member of
the TGF-beta superfamily of receptors with multiple biological functions, including the regulation
of proliferation and cell migration [32]. ACVR2A down-regulation has been linked to advanced
stage, lymphatic invasion and reduced survival, suggesting its prognostic significance in CRC [31].
Since ACVR2A mutations are most frequent in hypermutated CRCs, TRIB2 may be most suitable as a
therapeutic biomarker within this population, although the low proportion of patients with known
MSI-high disease limits conclusions for MSI-specific biomarkers.
VSIG4 (V-Set and Immunoglobulin Domain Containing 4) is a newly identified immune checkpoint
of the B7 family of immune regulatory proteins with similar functions as CTLA-4 and PD-1 in T-cell
inhibition. Surface expression of VSIG4 protein is restricted to resting macrophages [33]. Its expression
in tumor-associated macrophages is a potential facilitator of NSCLC development by inhibiting CD4+
and CD8+ T-cell proliferation and cytokine production [34]. In the current study, elevated VSIG4
expression was associated with the presence of disruptive ANK3 mutations and recurrent disease.
ANK3 (Ankyrin G) provides cellular stability by anchoring cytoskeleton to the plasma membrane, and
its down-regulation has been associated with poor prognosis [35] and increased invasive potential [36]
in solid malignancies. Potential immune checkpoint inhibitor therapy may be most relevant for patients
with upregulated VSIG4, especially those with simultaneous ANK3 mutations.
Bone morphogenetic proteins (BMPs) have received much attention due to their role in tumor
development and dissemination, and the wealth of conflicting studies indicates that BMPs may stimulate
tumorigenesis in one cancer type but suppress it in another [37]. The BMP4 (Bone Morphogenetic
Protein 4) gene encodes a secreted ligand of the TGF-beta superfamily of proteins, resulting in the
activation of SMAD family transcription factors [38]. BMP4 is overexpressed in CRC compared to
normal tissue [39], and BMP4-overexpressing clones created from HCT116 cells exhibit enhanced
migration and invasion [40]. In our data, BMP4 upregulation was associated with the presence of
SOX9 mutations. SOX9 (Sex-determining region Y (SRY)-box 9) is an intensely studied transcriptional
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factor, which plays critical roles in the development and lineage commitment of various tissues [41]. In
the intestinal epithelium, it is mainly expressed in the progenitor cells of the colon and small intestines
and plays a crucial role in stem-cell maintenance. It is also a downstream target of Wnt/β-catenin
signaling, with possible roles in β-catenin regulation [42]. There is growing evidence of the importance
of SOX9 in CRC development. SOX9 is mutated in 5–10% of all CRC cases [31] and leads to SOX9
overexpression [43]; this association is also confirmed in our dataset. It is likely a pro-oncogene,
as high SOX9 expression has been linked to advanced tumor stage [44] and adverse prognosis in
primary CRC [45]. BMP signaling and SOX9 interact in various developmental processes, such as
chondrogenesis and the regulation of stem cells [46]. Targeting BMP4 may thus provide a viable
therapeutic option, especially for patients with mesenchymal subtypes of CRC.
DUSP4 (Dual Specificity Phosphatase 4) is a negative regulator of mitogenic signal transduction
associated with proliferation and differentiation by dephosphorylating members of the MAPK
superfamily (ERK1, ERK2, JNK) [47]. Higher DUSP4 expression characterizes MSI-high cell lines
compared to microsatellite stable cells associated with increased cellular proliferation [48]. Consistently,
in our dataset, significant DUSP4 upregulation characterized tumors with various (ACVR2A, AKN3
and AMER1) mutations, with the highest expression in ACVR2A mutant cases. Both ACVR2A and
ANK3 mutations have been mainly observed in hypermutated/MSI-high tumors [31,49], however the
lack of information about MSI status for the majority of specimens does not allow conclusions for
MSI-specific biomarkers. AMER1 (APC Membrane Recruitment Protein 1) is a tumor suppressor
mutated in about 10% of CRC patients, especially in tumors with mesenchymal phenotypes linked to
canonical Wnt-pathway inhibition [50]. Tumors lacking AMER1 mainly belong to the EMT subtype
associated with poor prognosis and resistance to chemotherapy [50]. Thus, targeting DUSP4 may
provide a treatment approach for a wider selection of CRC patients with distinct molecular subtypes.
5. Conclusions
The evolution of precision medicine in CRC remains slow, with a limited efficacy of
single-mutation/single-drug approaches [11]. Nevertheless, linking the mutation status of oncogenes
with targetable opportunities in downstream signaling pathways provides a novel approach for therapy
development. The proposed biomarkers represent divergent biological mechanisms and may be
particularly suitable for distinct molecular subtypes of CRC. For example, ACVR2A mutations are
most frequent in hypermutated CRC and therefore, targeting up-regulated TRIB2 may potentially be
suitable in such tumors, while BMP4 may be a better suited biomarker for CRC patients with SOX9
mutations and mesenchymal subtypes. In contrast, multiple mutations result in DUSP4 upregulation,
providing a potential treatment for a larger selection of patients. The suggested biomarker-defined
patient stratification may provide an attractive approach toward therapy optimization.
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